title: Risk of venous thromboembolism due to antipsychotic drug therapy.
abstract: An increasing number of reports suggest a link between venous thromboembolism (VTE) and the use of antipsychotics. To better understand this association the available body of evidence has been critically scrutinised. Relevant articles were identified in the databases Scopus and PubMed. Several observational studies using different methodologies show an increased risk of VTE in psychiatric patients. This elevated risk seems to be related to the use of antipsychotic medication and in particular to the use of clozapine and low-potency first-generation drugs. Many studies investigating the association have, however, methodological limitations. The biological mechanisms involved in the pathogenesis of this possible adverse reaction are largely unknown but several hypotheses have been suggested such as drug-induced sedation, obesity, increased levels of antiphospholipid antibodies, enhanced platelet aggregation, hyperhomocysteinemia and hyperprolactinemia. The association may also be related to underlying risk factors present in psychotic patients. Physicians need to be aware of this possible adverse drug reaction. Although supporting evidence has not been published they should consider discontinuing or switching the antipsychotic treatment in patients experiencing VTE. In addition, although data is lacking, the threshold for considering prophylactic antithrombotic treatment should be low when risk situations for VTE arise, such as immobilisation, surgery and so on.
authors: Linköping University, Department of Drug Research, Section of Clinical Pharmacology, S-581 83 Linköping, Sweden. staffan.hagg@liu.se
authors: Staffan
authors: S
authors: Hägg
authors: Anna K
authors: AK
authors: Jönsson
authors: Olav
authors: O
authors: Spigset
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D002389:Catatonia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003645:Death, Sudden / Q000209:etiology; D003681:Dehydration / Q000097:blood / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D010974:Platelet Aggregation / Q000187:drug effects; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000401:mortality; D012149:Restraint, Physical / Q000009:adverse effects; D012189:Retrospective Studies; D012306:Risk; D012307:Risk Factors; D019851:Thrombophilia / Q000139:chemically induced* / Q000209:etiology; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine